GlassScriptPhysician profile
George C Smith
NPI 1285627828
$2,658.54
in general payments reported to CMS, 2019-2025
22 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $331 · 2021: $678 · 2022: $437 · 2023: $335 · 2024: $284 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $669.50 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $401.29 | 2019-2022 | |
| Abbvie INC. | $187.95 | 2021-2024 | Vraylar, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $182.15 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $163.70 | 2022-2024 | Rexulti |
| Amgen INC. | $147.19 | 2019-2023 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.55 | 2021-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $112.33 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Indivior INC. | $111.01 | 2024-2025 | Sublocade |
| Welch Allyn | $107.17 | 2021 | |
| Stryker Corporation | $72.83 | 2019 | |
| Lilly USA, LLC | $71.66 | 2019-2024 | Jardiance, Mounjaro |
| Mylan Specialty L.P. | $63.17 | 2022-2024 | Yupelri |
| Pfizer INC. | $60.54 | 2024 | |
| Avanir Pharmaceuticals, INC. | $38.74 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $29.73 | 2022 | |
| Melinta Therapeutics, LLC | $27.94 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.87 | 2025 | |
| Verona Pharma, INC. | $16.36 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.43 | 2019 | |
| Celgene Corporation | $14.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.